Assessing Prognosis in Hodgkin Lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on improving the prognostic assessment of Classical Hodgkin Lymphoma (cHL) by utilizing both retrospective and prospective cohorts. It includes patients who have completed treatment and are in follow-up, as well as those with confirmed relapse or progression. The study aims to integrate novel tools for monitoring tumor complexity and anticipating disease progression, addressing the limitations of current prognostic methods. By analyzing clinical, laboratory, and imaging data alongside liquid biopsy samples, the study seeks to enhance personalized treatment strategies for cHL patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \>18 anni
* Written informed consent signed

Cohort A

* Age \>18 years
* Histologically confirmed diagnosis of relapsed/refractory classical Hodgkin lymphoma identified during induction or follow-up
* Available formalin-fixed, paraffin-embedded (FFPE) biopsy at diagnosis and at the time of progression/relapse
* Available plasma sample at progression (before the beginning of salvage therapy)
* Available FDG-PET evaluation at study enrollment
* Available clinical, laboratory, and radiologic data at diagnosis and relapse

Cohort B

* Diagnosis of classical Hodgkin lymphoma
* Completion of first-line standard systemic treatment (chemotherapy-based or chemoradiotherapy combined modality)
* Available plasma sample at the end of treatment (at least 30 days from the last chemotherapy)
* Available FFPE biopsy at diagnosis
* No further treatment planned
* Available clinical, laboratory, and radiologic data at diagnosis and response evaluation
* Patient's willingness to undergo 6 months follow-up plasma sample collection and to attend regular follow-up

Cohort C

* Histologically confirmed diagnosis of classical Hodgkin lymphoma
* Standard treatment as per available guidelines (e.g., ESMO guidelines)
* Available treatment data, response, and follow-up data
* Available FFPE biopsy at diagnosis
* Available FDG-PET evaluation at study enrollment

Exclusion Criteria:

* Patients with nodular lymphocyte predominant Hodgkin lymphoma are not eligible; all other subtypes including nodular sclerosis, lymphocyte-depleted, lymphocyte-rich, and mixed cellularity Hodgkin lymphoma may be enrolled.
* Active HIV, HBV, HCV viral infection
* Concomitant neoplasm not treated with a curative aim

Where it's running

• ASST Grande Ospedale Metropolitano Niguarda
  Milan, Mi, Italy Recruiting
• Azienda USL IRCCS di Reggio Emilia
  Reggio Emilia, Re, Italy Recruiting
• A.O.S.G. Moscati
  Avellino, Italy Recruiting
• Spedali Civili Brescia
  Brescia, Italy Recruiting
• Istituto Oncologico Veneto
  Padova, Italy Recruiting
• Azienda Ospedaliera "Ospedali Riuniti Villa Sofia-Cervello"
  Palermo, Italy Recruiting

Study contacts

• Principal investigator: Luminari Stefano, MD — Azienda USL Reggio Emilia - IRCCS
• Study coordinator: Attilio Gennaro, Clinical Research Coordinator
• Email: attilio.gennaro@ausl.re.it
• Phone: +39 0522 295175

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blood ctDNA testing to monitor treatment in children and young adults with classical Hodgkin lymphoma

  This project tests whether a blood test that detects circulating tumor DNA can monitor treatment response and help predict relapse in children and young adults with classical Hodgkin lymphoma.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07356882

• Sintilimab combined with AVD chemotherapy for treating pediatric Hodgkin lymphoma

  This study is testing if a new immunotherapy combined with standard chemotherapy can help children and teens with low-to-intermediate risk Hodgkin lymphoma feel better and improve their treatment results.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06848569

• Using Brentuximab Vedotin to treat newly diagnosed Classical Hodgkin Lymphoma in young patients

  This study is testing if a new treatment with Brentuximab vedotin can help young patients with newly diagnosed classical Hodgkin lymphoma feel better while reducing the need for chemotherapy and radiation.

  Recruiting Phase 2/3 Children's Cancer Group, China · Shanghai · NCT06563245

• Healthy Lifestyle Plan for Lymphoma Survivors

  This study is testing whether a special health plan that includes lifestyle changes and nutrition advice can help lymphoma survivors feel better after they've been in remission for a while.

  Recruiting at 34 sites Fondazione Italiana Linfomi - ETS · Ancona, Ancona and 39 other locations · NCT05934084

• Combining pembrolizumab with chemotherapy for relapsed Hodgkin lymphoma

  This study is testing if adding pembrolizumab to standard chemotherapy can help people with relapsed Hodgkin lymphoma feel better and have fewer side effects.

  Recruiting Phase 2 University of Cologne · Cologne · NCT04838652

• Individualized immunotherapy for early-stage Hodgkin lymphoma

  This study is testing a personalized treatment using a new drug for young people with early-stage Hodgkin lymphoma to see if it can help them avoid harsh chemotherapy and improve their quality of life.

  Recruiting Phase 2 University of Cologne · Cologne · NCT04837859

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.